Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry ...
A phase II randomized placebo-controlled study of fisetin and exercise to mitigate chemotherapy-related functional decline in postmenopausal women with early breast cancer (PROFFi). This is an ASCO ...
Dr Mark Kris examines new OS results for chemo plus osimertinib in EGFR-mutant NSCLC and how they align with survival gains seen previously with other EGFR TKIs.
The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement. Also, ...
Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.
The Prescription Drug User Fee Act target date has been set for the third quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results